Methyl salicylate / Sweet Birch oil / cMyc Cancer Research Results

MeSal, Methyl salicylate / Sweet Birch oil: Click to Expand ⟱
Features:

Methyl salicylate / Sweet Birch oil — Methyl salicylate is a small lipophilic salicylate ester and the dominant constituent of sweet birch oil and wintergreen oil. It is best classified as a natural-product-derived topical counterirritant / salicylate prodrug rather than a practical systemic anticancer agent. Natural sources include Betula lenta sweet birch and Gaultheria procumbens wintergreen, but commercial methyl salicylate is also commonly synthetic. Its cancer relevance is mainly mechanistic and indirect through salicylate biology, with major translation limits from toxicity, dermal absorption variability, and the high millimolar concentrations used in many cell studies.

Primary mechanisms (ranked):

  1. Hydrolysis to salicylate / salicylic acid, linking methyl salicylate to salicylate pharmacology rather than a distinct validated anticancer modality.
  2. COX and prostaglandin-axis suppression, reducing inflammatory signaling that can support tumor promotion and pain/inflammation pathways.
  3. NF-κB pathway inhibition, with potential suppression of survival, inflammatory, invasion, and therapy-resistance signaling in cancer contexts.
  4. AMPK activation with downstream c-MYC suppression and NRF2/ARE/miR-34a/b/c activation, reported for salicylate in colorectal cancer models.
  5. p38 MAPK-linked apoptosis and cell-cycle effects, mostly from sodium salicylate studies at pharmacologic-to-high in-vitro concentrations.
  6. Secondary mitochondrial stress / oxidative phosphorylation disruption at toxic or high concentrations, more relevant to safety than selective anticancer translation.

Bioavailability / PK relevance: Methyl salicylate is lipophilic and can penetrate skin; dermal absorption and systemic salicylate exposure are strongly formulation-, area-, dose-, heat-, and occlusion-dependent. It is rapidly hydrolyzed to salicylate, so systemic effects and toxicity resemble salicylate exposure. Oral or concentrated essential-oil exposure is a major toxicity concern and should not be treated as a supplement-like route.

In-vitro vs systemic exposure relevance: Many anticancer mechanistic studies use sodium salicylate or salicylate at millimolar concentrations, which generally exceed realistic or safe exposure targets for methyl salicylate oil. Topical use can create local tissue exposure and systemic salicylate exposure, but this is not a controlled anticancer delivery strategy. Mechanistically relevant but clinically constrained.

Clinical evidence status: Cancer evidence is preclinical / indirect, mostly extrapolated from salicylate and aspirin biology rather than methyl salicylate as an anticancer intervention. Human evidence supports topical analgesic / counterirritant use, not cancer treatment. Regulatory deployment is OTC topical analgesic/counterirritant in some jurisdictions and cosmetic/fragrance ingredient under concentration limits, with important salicylate toxicity, skin burn/irritation, sensitization, renal disease, anticoagulant, and pediatric safety constraints.

Methyl Salicylate Mechanistic Ranking

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Salicylate prodrug conversion ↔ methyl salicylate-specific targeting; ↑ salicylate exposure after hydrolysis ↑ systemic salicylate burden after dermal or oral exposure R Functional conversion to salicylate biology Most mechanistic cancer claims should be attributed to salicylate / salicylic acid rather than sweet birch oil as a complex essential oil.
2 COX prostaglandin inflammatory signaling ↓ prostaglandin-linked inflammatory support (context-dependent) ↓ inflammatory pain signaling; potential platelet / renal / gastric salicylate constraints if systemic R-G Anti-inflammatory counterirritant / salicylate effect Relevant to tumor-promoting inflammation but not a selective anticancer mechanism.
3 NF-κB survival and inflammatory signaling ↓ NF-κB activation; ↑ TNF-linked apoptosis in some cancer models ↓ inflammatory gene expression; possible impaired protective inflammatory responses R-G Reduced survival and inflammatory transcription Evidence is strongest for salicylate / aspirin class biology, not methyl salicylate oil itself.
4 AMPK c-MYC NRF2 miR-34 cascade ↑ AMPK; ↓ c-MYC; ↑ NRF2/ARE; ↑ miR-34a/b/c; ↓ migration / invasion in colorectal cancer models ↑ AMPK metabolic signaling (context-dependent) G Metabolic and tumor-suppressive microRNA modulation Mechanistically interesting for colorectal cancer, but based on salicylate concentrations that may not be safely achievable from methyl salicylate oil.
5 p38 MAPK apoptosis ↑ p38 MAPK; ↑ apoptosis (high concentration only) ↑ stress-response apoptosis risk at toxic exposure R-G Stress-activated apoptosis Useful as a mechanistic flag, but selectivity is uncertain and concentration dependence is a major limitation.
6 Mitochondrial stress and oxidative phosphorylation disruption ↑ metabolic stress (toxic concentration only) ↑ systemic toxicity risk; acid-base disturbance risk with overdose R-G Toxic salicylate pharmacology This is mainly a safety constraint rather than a therapeutic anticancer mechanism.
7 Clinical Translation Constraint ↔ no validated anticancer exposure strategy ↑ dermal absorption variability; ↑ toxicity risk with ingestion, damaged skin, large-area use, heat, occlusion, renal disease, anticoagulants, or aspirin sensitivity R-G Translation limited by toxicity and exposure control Best database placement is “mechanistic / preclinical salicylate-related,” not an actionable cancer therapy listing.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr
cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
Scientific Papers found: Click to Expand⟱
6538- MeSal,  ASA,    Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis
- in-vitro, CRC, NA
chemoPv↑, AMPK↑, NRF2↑, miR-34a↑, cMyc↓, tumCV↓, Apoptosis↑, TumCI↓, TumCMig↓, MET↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

miR-34a↑, 1,  

Migration ⓘ

MET↑, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:412  Target#:35  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page